Search the Newsreel

Price to sales forward of Burning Rock Biotech Ltd. Sponsored ADR – FWB:6BU0

This article provides financial information for Burning Rock Biotech Ltd. Sponsored ADR (FWB:6BU0) on TradingView. It specifies the "Price to sales forward" metric for the company, indicating the data was made by humans. The content primarily focuses on navigation and platform features rather than …

XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for XBiotech Inc (XBIT), focusing on future EPS and revenue growth estimates. As of August 9, 2026, the company's stock is trading at 2.275 USD, with a market cap of 69.36M. The forecast section includes details on EPS, …

Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 130th out of 156 companies in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with a range from $2.00 to $7.00. The company's next …

Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Hong Kong Stock Market Movement | GenScript Biotech Corporation (01548.HK) Rises Over 8% as AIDD Boosts Demand for Experimental Validation; Institutions Bullish on Strengthened 'Shovel Seller' Thesis

Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?

Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)

Adaptive Biotechnologies (ADPT) Is Up 10.5% After Raising 2026 MRD Revenue Guidance Has The Bull Case Changed?

Sana Biotechnology faces earnings test as CAR-T program advances

Sana Biotechnology Inc. is set to report its second-quarter results on Monday, with analysts expecting a narrower loss of 15 cents per share and no revenue. Investors will be closely watching for updates on its in vivo CAR-T platform, specifically SG293, and its stem …

Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT

Renaissance Technologies LLC has acquired 239,800 shares of Adaptive Biotechnologies Corporation, valued at approximately $3.33 million, marking a new stake in the company. Institutional investors collectively hold 99.17% of Adaptive Biotechnologies. The company reported better-than-expected quarterly revenue but missed earnings estimates, while analysts maintain …

PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates

PharmaCyte Biotech Inc (PMCB) Stock News Today

This article provides current stock information for PharmaCyte Biotech Inc (PMCB), including its latest stock price, daily change, market cap, and links to financial data, analyst ratings, and news. As of the report, PMCB closed at $0.553 with a 1.37% increase, and indicated that …

Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades

Puma Biotechnology (PBYI) saw its stock jump 9.7% after reporting strong Q2 2026 earnings, driven by NERLYNX revenue and increased net income. While current profitability and raised full-year guidance are positive, analysts project weaker earnings in the future, creating a tension between present strength …

Did Stronger Q2 2026 Profitability Just Shift Krystal Biotech's (KRYS) Investment Narrative?

XBiotech Inc (XBIT) Stock News Today

This article from TradingKey provides a news and analysis page for XBiotech Inc (XBIT) stock. It shows the current stock price, market cap, and links to various financial data and analytical tools. The page indicates that more news is expected soon.

Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position

State Street Corporation, through its investment management subsidiaries, has disclosed a beneficial ownership of 9,964,151 shares of Vir Biotechnology, Inc. common stock, which represents 5.9% of the class as of June 30, 2026. The filing indicates that all voting and dispositive authority is held …

1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. has acquired 1,915,056 shares of Legend Biotech Corporation (NASDAQ:LEGN) worth approximately $55.3 million, giving it a 1.03% stake. Institutional investors now own 70.89% of the company, and analysts generally have a "Moderate Buy" rating with an average price target of …

VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform

VERAXA Biotech is making significant strides in antibody therapeutics with its proprietary BiTAC platform, focusing on bispecific ADCs and T-cell engagers. The company's platform is designed for precision and efficacy, positioning it for potential partnerships and licensing deals in the rapidly growing market for …

Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Sana Biotechnology Inc (SANA) has a target price of USD 7.00, with analysts forecasting a potential upside of 151.36%. Based on ratings from 9 analysts, the consensus for SANA stock is a "Buy." The company's EPS for the previous quarter was USD -0.21, and …

What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders

Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with US$80.08 million in net income and sharply increased revenue of US$238.95 million. Despite this improvement, the company missed analyst expectations for both earnings and sales. The article discusses how this mixed …

Purple Biotech Posts Q2 2026 Results as IM1240 Preclinical Data Strengthen Immunotherapy Platform

Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates

Oncolytics Biotech Inc (ONCY) has an earnings forecast score of 7.67, ranking 274 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $5.25 for ONCY, with a high of $10.00 and a low of $3.00, …

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded Vir Biotechnology (NASDAQ:VIR) from a "sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with a $20.62 target price. The company recently reported strong quarterly earnings, beating EPS and revenue estimates significantly, with revenue …

Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS

PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PharmaCyte Biotech Inc (PMCB), detailing future EPS and revenue growth estimates. It includes a snapshot of the company's current stock price, market capitalization, and various financial metrics. The article also lists peer comparisons and indicates that the …

Zhengye Biotechnology Holding Ltd (ZYBT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Zhengye Biotechnology Holding Ltd (ZYBT), focusing on future EPS and revenue growth estimates. As of August 8, 2026, ZYBT's stock closed at $1.890 USD, down 9.57%, with a market cap of $89.57 million. The page includes an …

Should You Investigate Genscript Biotech Corporation (HKG:1548) At HK$22.98?

Trinity Biotech PLC (TRIB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Trinity Biotech PLC (TRIB), focusing on future EPS and revenue growth estimates. It includes current stock information, market cap, and a comparison with peer companies in the healthcare equipment sector. The data presented was last updated on …

TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock

Trinity Biotech PLC (TRIB) Stock News Today

This article provides current stock information for Trinity Biotech PLC (TRIB), showing its recent trading performance with a 6.79% increase. It notes that more news is expected soon regarding earnings, analyst ratings, and key developments. The page also includes financial data like market capitalization.

Legend Biotech Details Compensation Package for Interim CEO Alan Bash

PPBT Maintained by HC Wainwright & Co. -- Price Target Lowered t

Law firm investigates Fortress Biotech for poss...

A law firm, Levi & Korsinsky, has initiated an investigation into Fortress Biotech, Inc. regarding potential breaches of fiduciary duties. This inquiry is focused on the company's financial management and accountability, and shareholders are encouraged to seek legal advice without cost. The investigation could …

FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after market close on August 12.

FORTRESS BIOTECH INC (FBIOP.US) is scheduled to release its earnings report after the market closes on August 12. This announcement alerts investors and stakeholders to the upcoming financial disclosure for the company's 9.375% Cumulative Redeemable Preferred Stock Series A.

Why Cannara Biotech Inc. stock is sliding today

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised